164 results on '"Schuch G"'
Search Results
2. One human settlement: A transdisciplinary approach to climate change adaptation research
3. 681P OPTIM: A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck – AIO-KHT-0117
4. LBA59 Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial
5. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
6. Improving cross-sectoral climate change adaptation for coastal settlements: insights from South East Queensland, Australia
7. Equipment improvement trends in distillation
8. Adjuvante Therapie des Kolonkarzinoms
9. CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer
10. Studien zum Kolorektalkarzinom
11. Précurseurs et dérivés du PSA : application en clinique, revue de la littérature
12. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo
13. 1443P Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO
14. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
15. Efficacy of Further Attempts to Mobilize CD34+ Peripheral Stem Cells with Alternative Procedures after Primary Failure
16. Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase II trial of the German Gastric Group of the AIO
17. A randomized phase II study on the OPTimization of Immunotherapy in squamous carcinoma of the head and neck (SCCHN) - OPTIM (AIO-KHT-0117)
18. Entwicklung antiangiogener Kombinationstherapien zur Behandlung des Nierenzellkarzinoms
19. Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study
20. Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study
21. 1173TiP - A randomized phase II study on the OPTimization of Immunotherapy in squamous carcinoma of the head and neck (SCCHN) - OPTIM (AIO-KHT-0117)
22. 835TiP - Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase II trial of the German Gastric Group of the AIO
23. PD-020 - Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study
24. S3-Leitlinie 'Magenkarzinom' – Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs
25. 486O - Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study
26. Elevated Pretreatment Serum Concentration of YKL-40-An Independent Prognostic Biomarker for Poor Survival in Patients With Metastatic Nonsmall Cell Lung Cancer
27. Improving cross-sectoral climate change adaptation for coastal settlements: insights from South East Queensland, Australia
28. S3-Leitlinie „Magenkarzinom” -
29. Severe aplastic anaemia following leflunomide therapy
30. 6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4± cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study
31. Activity of lenalidomide in metastatic hepatic epithelioid hemangioendothelioma (HEH): A case report
32. Précurseurs et dérivés du PSA : nouveaux marqueurs dans les pathologies prostatiques ?
33. Elevated pretreatment serum concentration of YKL-40—An independent prognostic biomarker for poor survival in patients with metastatic non-small cell lung cancer
34. Hydraulische Untersuchungen zur Steigerung der Kapazität von Böden in Destillationskolonnen
35. 3502 ORAL Final results of a randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)
36. Analysis of 94 patients with advanced biliary tract cancer
37. The tyrosine kinase src plays a crucial role in leukemic cell proliferation in AML
38. Comparison of combination treatment with endostatin, soluble neuropilin-1 and thrombospondin-2 to single inhibitors in antiangiogenic therapy of renal cell carcinoma
39. A pilot study of weekly docetaxel and daily trofosfamide as metronomic second-line chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC)
40. Detection of circulating lymphendothelial cells in patients with solid tumors
41. A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)
42. Correlation of pre-treatment serum levels of Magic Roundabout protein with overall survival in patients with advanced non-small cell lung cancer (NSCLC)
43. Pancreatic tumor growth is regulated by the balance of positive and negative modulators of angiogenesis
44. In vitro differentiation of endothelial cells (EC) from AC133-positive progenitor cells
45. Foreword
46. 159. Zum Scale-up von Destillationskolonnen
47. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
48. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
49. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
50. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.